Panacea Biotec Swings to Profit in Q1, Revenue Surges 44%
Panacea Biotec reported a consolidated net profit of ₹41 crore in Q1, compared to a loss of ₹158 crore last year. Revenue increased 44% to ₹1,667 crore. The company recorded an exceptional item of ₹113 crore, including ₹85.80 crore from a settlement with Apotex Inc. and ₹27.40 crore from brand sales. The vaccines segment reported revenue of ₹1,122.50 crore with a loss, while formulations generated ₹544.50 crore with a profit. The company is focusing on expanding vaccine manufacturing capacities and scaling up its nutrition and pharmaceutical formulations business.
29Jul 25
Panacea Biotec Secures Exchange Approval for Reclassification of Three Jain Family Members
Panacea Biotec Limited has received approval from BSE and NSE to reclassify three Jain family members from 'Promoters and Promoters' Group' to 'Public' category. The reclassification, approved on July 29, 2025, applies to Mrs. Sunanda Jain, Mr. Sumit Jain, and Ms. Radhika Jain. This change does not affect the company's shareholding structure, as the reclassified members hold no shares. Promoter holding remains at 72.48% and public holding at 27.52%. The reclassification complies with SEBI regulations.
11Jul 25
Panacea Biotec Faces Fresh GST Demand of 70.3 Million Rupees
Panacea Biotec has received a new GST demand of ₹70.3 million from the Assistant Commissioner of State Tax in Mumbai. This demand is related to a previous tax matter involving the transfer of leasehold rights in Navi Mumbai. The total amount includes ₹38.8 million in principal GST, ₹25.1 million in interest, and ₹6.5 million in penalties. Panacea Biotec believes the demand is not maintainable and is considering filing an appeal. The company does not expect this to significantly impact its financial or operational activities.
26Jun 25
Panacea Biotec May Face Challenges as US Halts Support for Global Vaccine Alliance Gavi
The US Health Secretary has announced a halt to support for the Global Vaccine Alliance (Gavi), which could have significant implications for vaccine manufacturers worldwide, including Panacea Biotec. This decision may affect vaccine distribution channels, ongoing research collaborations, market access in developing countries, and potentially the financial outlook for companies involved in Gavi-supported initiatives. The full impact on Panacea Biotec's operations remains uncertain, and stakeholders are advised to monitor for official statements from the company.
03Jun 25
Panacea Biotech's Emulsipan Adjuvant Gains Recognition in CEPI Library
Panacea Biotech announced the inclusion of its proprietary Emulsipan adjuvant in the Coalition for Epidemic Preparedness Innovations (CEPI) Adjuvant Library. This recognition highlights Emulsipan's potential in enhancing vaccine efficacy. The company also plans to commercialize its indigenously developed adjuvants, potentially opening new revenue streams. This development could enhance Panacea Biotech's global visibility, lead to new collaborations, and contribute to global health efforts in vaccine development.
30May 25
Panacea Biotec Reports Q4 Net Loss of ₹19 Crore, Revenue Dips
Panacea Biotec's Q4 financial results show a net loss of ₹19 crore, compared to a ₹14 crore loss in the same quarter last year. Revenue decreased by 4.41% year-on-year to ₹130 crore. This marks a shift from the previous quarter's profit of ₹45 crore, indicating volatility in the company's financial performance.
23Apr 25
Panacea Biotec Secures Additional $5.20 Million UNICEF Contract, Boosting Total Order Value to $20.15 Million
Panacea Biotec has expanded its contract with UNICEF for bivalent oral polio vaccine (bOPV) supply. The initial order of 115 million doses worth $14.95 million has been increased by an additional 40 million doses valued at $5.20 million. The total contract value now stands at $20.15 million (₹171.00 crore). The additional order will be delivered in Q3 CY2025, reinforcing the company's position in the global vaccine market and contributing to polio eradication efforts.